Google
KRBP — KIROMIC BIOPHARMA INC (Healthcare >> Biotechnology)
KRBP FAQ
What is KRBP's ROE?
KIROMIC BIOPHARMA INC reports a Return on Equity (ROE) of 213.70%.
What is KRBP's dividend yield?
KIROMIC BIOPHARMA INC offers a dividend yield of 0.00%.
What is KRBP's Deepscope Quality Score?
Deepscope rates KRBP's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KRBP?
Deepscope's AI Timing Score for KRBP is 6 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KRBP belong to?
KIROMIC BIOPHARMA INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 21.75
Price
0.00
(0.00%)
Day Change
|
|
|---|
KRBP, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 65 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 21.75 |
| PBV / Sector |
-49.27 / 4.63
|
| Earning Per Share | -1.03 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
33.983625000000
GREAT
|
| Average 1W Daily Value |
34.924000000000
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:48 |
| Symbol | KRBP |
| Name | KIROMIC BIOPHARMA INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 2.65 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 620.13 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7707 Fannin Street, Houston, TX, United States, 77054
Phone: 832 968 4888
Website: https://www.kiromic.com
Sector: Healthcare >> Biotechnology
Description: Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. On March 21, 2025, Kiromic BioPharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
